A Phase 3 interventional study of open-label rifaximin and double-blind placebo in Irritable Bowel Syndrome With Diarrhea, sponsored by Bausch Health Americas, Inc.. Completed at 296 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-12.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.
Among the 19 studies testing rifaximin in Diarrhea, this one has the largest enrollment, is one of 2 that started in 2012, is one of 10 in phase 3, and was the 11th registered.
879 studies on the registry are indexed under Diarrhea; 77 are open to participants now.
Browse Diarrhea studies →1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2012.
This study's enrollment of 2,583 is above the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 210 across the 19 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
11 studies in Diarrhea by Bausch Health Companies Inc.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 8 (80%) have results posted.
Among the 11 studies in Diarrhea by Bausch Health Companies Inc., this one has the largest enrollment, is the only one that started in 2012, is one of 8 in phase 3, and was the 10th registered.
Bausch Health Companies Inc.’s Diarrhea studies by the year they started, since 2004.
1 of the studies testing rifaximin in Diarrhea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing rifaximin in Diarrhea, from their registry updates:
Among Bausch Health Companies Inc.’s 11 in Diarrhea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
It is important in chronic conditions to have information about how a product that is intended for short course administration in order to confer prolonged benefit should be administered beyond the first cycle of use once symptoms reappear. This Phase 3 study will evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg three times daily (TID) for 14 days in subjects with IBS-D who respond to an initial treatment course with rifaximin 550 mg TID for 14 days.
This study consists of several treatment phases outlined below:
Screening/Treatment 1 Phase. Subjects will receive single-blind placebo TID for 7-13 days and answer daily IBS symptom-related questions.
Treatment 2 Phase. Eligible subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1. Nonresponders will withdraw from the study.
Maintenance Phase 1. Subjects will continue the treatment-free follow-up period for up to 18 weeks until either: 1) they experience recurrence or 2) enrollment is met in the Treatment 3 Phase (Double Blind Repeat Treatment Phase). Subjects who do not meet recurrence criteria by the end of the Maintenance Phase 1 will withdraw from the study.
Treatment 3 Phase/ Double Blind Repeat Treatment Phase. Subjects who meet criteria for recurrence will be randomized 1:1 to receive either rifaximin 550 mg TID or placebo TID for 2 weeks with a 4-week treatment-free follow-up.
Primary efficacy analysis will be performed at the end of the Treatment 3 Phase (at Week 6 of the double-blind period).
Maintenance Phase 2. All subjects continued into an additional treatment-free follow-up period of up to 6 weeks (Maintenance Phase 2).
Treatment 4 Phase/Second Repeat Treatment Phase. Subjects will receive the same double-blind treatment as previously assigned in the Treatment 3 Phase for 2 weeks with a 4-week treatment-free follow-up.
A lactulose breath test sub-study will be conducted at select sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study. Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo.
Drug: open-label rifaximin
Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
Drug: open-label rifaximin · Drug: double-blind rifaximin
Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
Drug: open-label rifaximin · Drug: double-blind placebo
550 mg three times a day (open-label)
Also known as: rifaximin
3 times a day (double-blind)
Also known as: Placebo
550 mg three times a day (double-blind)
Also known as: rifaximin
Repeat Treatment Responders
Subjects who respond to repeat treatment in both IBS-related abdominal pain and stool consistency. The proportion of patients who responded to repeat treatment during the first double-blind repeat treatment phase is presented. Response is defined as improvement from baseline in abdominal pain AND reduction from baseline in diarrhea.
Time frame: 4-week treatment-free follow-up in double-blind repeat treatment phase.
| Milestone | Open-label Rifaximin | Double-blind Rifaximin (Retreatment) | Double-blind Placebo (Retreatment) |
|---|---|---|---|
| Started | 2583 | 0 | 0 |
| Completed | 636 | 0 | 0 |
| Not completed | 1947 | 0 | 0 |
| Milestone | Open-label Rifaximin | Double-blind Rifaximin (Retreatment) | Double-blind Placebo (Retreatment) |
|---|---|---|---|
| Started | 0 | 328 | 308 |
| Completed | 0 | 284 | 271 |
| Not completed | 0 | 44 | 37 |
Subjects who respond to repeat treatment in both IBS-related abdominal pain and stool consistency. The proportion of patients who responded to repeat treatment during the first double-blind repeat treatment phase is presented. Response is defined as improvement from baseline in abdominal pain AND reduction from baseline in diarrhea.
| percentage of patients | Double-blind Rifaximin (Retreatment) | Double-blind Placebo (Retreatment) |
|---|---|---|
| Repeat Treatment Responders | 32.6 | 25.0 |
Collected over Up to 24 weeks for the open-label period. Up to 18 weeks for the double-blind period.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total Open-label Experience | — | 28/2,579 (1.1%) | 198/2,579 (7.7%) |
| Double-blind Retreatment Experience - Rifaximin Group | — | 4/328 (1.2%) | 74/328 (22.6%) |
| Double-blind Retreatment Experience - Placebo Group | — | 4/308 (1.3%) | 69/308 (22.4%) |
| Event | Total Open-label Experience | Double-blind Retreatment Experience - Rifaximin Group | Double-blind Retreatment Experience - Placebo Group |
|---|---|---|---|
| Transient ischaemic attackNervous system disorders | 1/2579 | 0/328 | 2/308 |
| Coronary artery occlusionCardiac disorders | 0/2579 | 0/328 | 1/308 |
| Non-cardiac chest painGeneral disorders | 4/2579 | 0/328 | 1/308 |
| CellulitisInfections and infestations | 1/2579 | 0/328 | 1/308 |
| HypertensionVascular disorders | 1/2579 | 0/328 | 1/308 |
| Clostridium difficile colitisInfections and infestations | 0/2579 | 1/328 | 0/308 |
| FallInjury, poisoning and procedural complications | 0/2579 | 1/328 | 0/308 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2579 | 1/328 | 0/308 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/2579 | 1/328 | 0/308 |
| Rectal haemorrhageGastrointestinal disorders | 2/2579 | 0/328 | 0/308 |
| Event | Total Open-label Experience | Double-blind Retreatment Experience - Rifaximin Group | Double-blind Retreatment Experience - Placebo Group |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 35/2579 | 11/328 | 15/308 |
| NauseaGastrointestinal disorders | 52/2579 | 12/328 | 7/308 |
| Upper respiratory tract infectionInfections and infestations | 41/2579 | 12/328 | 8/308 |
| NasopharyngitisInfections and infestations | 36/2579 | 10/328 | 9/308 |
| HeadacheNervous system disorders | 42/2579 | 4/328 | 9/308 |
| BronchitisInfections and infestations | 15/2579 | 9/328 | 5/308 |
| Alanine aminotransferase increasedInvestigations | 24/2579 | 9/328 | 4/308 |
| Blood creatine phosphokinase increasedInvestigations | 31/2579 | 9/328 | 3/308 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/2579 | 3/328 | 8/308 |
| SinusitisInfections and infestations | 34/2579 | 7/328 | 7/308 |
Baseline results were summarized for the safety population, defined as patients who received at least 1 dose of study drug. Results are presented for patients in the open-label period only (1943) and for patients who eventually were randomized to rifaximin (329) or placebo (308) (ie, participated in both open-label and double-blind periods).
| Age, Categorical(Participants) | Open-label Rifaximin Only | Double-blind Rifaximin (Retreatment) | Double-blind Placebo (Retreatment) | Total |
|---|---|---|---|---|
| <=18 years | 8 | 0 | 1 | 9 |
| Between 18 and 65 years | 1763 | 289 | 278 | 2330 |
| >=65 years | 172 | 39 | 29 | 240 |
| Age, Continuous(years) | Open-label Rifaximin Only | Double-blind Rifaximin (Retreatment) | Double-blind Placebo (Retreatment) | Total |
|---|---|---|---|---|
| Mean | 46.3 ± 13.5 | 47.9 ± 14.2 | 45.6 ± 13.8 | 46.4 ± 13.7 |
| Sex: Female, Male(Participants) | Open-label Rifaximin Only | Double-blind Rifaximin (Retreatment) | Double-blind Placebo (Retreatment) | Total |
|---|---|---|---|---|
| Female | 1319 | 222 | 219 | 1760 |
| Male | 624 | 106 | 89 | 819 |
Showing the first 100 of 296 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →